COMMUNIQUÉS West-GlobeNewswire

ProMIS Neurosciences Issues Year-to-Date Update, Highlighting 2018 Accomplishments
20/11/2018
Development of therapeutic antibodies for Alzheimer’s disease, Parkinson’s disease and ALS are top priorities for drug development and potential partnering TORONTO and CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE [...]
Radient Technologies Inc. Receives Confirmation of Readiness Letter from Health Canada
20/11/2018
EDMONTON, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) ( TSX Venture: RTI ) is pleased to announce that it has received its Confirmation of Readiness (“COR”) Letter [...]
IMV Moves to Develop DPX-Survivac as Monotherapy for Recurrent Ovarian Cancer
20/11/2018
IMV Will Host an Investor Call Today at 8:00 a.m. ET to Discuss the Updates to Its Clinical Program DARTMOUTH, Nova Scotia, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno- [...]
Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting
20/11/2018
SAN DIEGO and TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target [...]
New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted
20/11/2018
Oasmia Pharmaceutical AB (Nasdaq: OASM) announces that the United States Patent and Trademark Office (USPTO) has issued a notification of allowance of a patent for its unique nanotech method to produce novel [...]
BeiGene to Present at the 30th Annual Piper Jaffray Healthcare Conference
20/11/2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Surface Oncology Announces Upcoming Investor Presentations
20/11/2018
CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced [...]
Eloxx Pharmaceuticals To Present at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018
20/11/2018
WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic [...]
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
20/11/2018
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. Ms. Heggie currently [...]
Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
20/11/2018
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Clinical Data from Long-Term Safety-Study of Company’s Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting
20/11/2018
PHOENIX, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory pediatric epilepsy will be [...]
Ovid Therapeutics Announces OV935/TAK-935 Presentations at the American Epilepsy Society 72nd Annual Meeting
20/11/2018
NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today [...]
Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA)
20/11/2018
NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced [...]
ProQR to Present at the Evercore ISI HealthConX Conference
20/11/2018
LEIDEN, the Netherlands, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe [...]
VBL Therapeutics Announces Third Quarter 2018 Financial Results
20/11/2018
Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel, Nov. 20, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the third quarter ended September 30, [...]
Medigus Will Form a Separate Company for Its Novel Miniature Video Cameras, Focused on Marketing for New Industries
20/11/2018
The Fully Owned Subsidiary Will Engage in Promoting to New Additional Industries such as Defense, Aviation, Automotive and More OMER, Israel, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Medigus Ltd. (“Medigus” or the “Company”) ( [...]
Cambrex to Acquire Avista Pharma Solutions, Adding Early Stage API and Finished Dosage Form Development & Testing Services to its Global Contract Development & Manufacturing Network
20/11/2018
-- Conference Call at 8:30 a.m. ET Today -- EAST RUTHERFORD, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active [...]
Emblem Corp. Reports Strong Third Quarter 2018 Financial Results
20/11/2018
Revenues increase 281% over the quarter ended September 30, 2017 and 50% over Q2 2018 TORONTO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), a licensed producer of [...]
Tetra Bio-Pharma Enters into Binding Proposal with Quantum Pharma Inc.
20/11/2018
Company takes a significant step forward to become a fully integrated drug development company ORLEANS, Ontario, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc. (“ Tetra ” or “ TBP ”), (TSX VENTURE: TBP) (OTCQB [...]

Pages